AIM ImmunoTech releases video segment on Ebola and Ampligen

AIM ImmunoTech Inc. (NYSE American: AIM) said on June 4, 2026 that it released a Virtual Investor "What This Means" video segment. The segment features Chief Executive Officer Thomas Equels, Consulting Medical Officer Charles Lapp, MD, and Consulting Science Officer Christopher Nicodemus, MD. It discusses the ongoing Bundibugyo (BDBV) Ebola outbreak and what the company describes as the lack of approved targeted therapies or vaccines for that strain. The company also made available an updated Ebola-focused corporate presentation under the Presentations section of its Investors page.

Equels stated: "BDBV is a lethal, out-of-control disease. Infected patients can receive aggressive supportive care, but there are no approved vaccines, therapies or meaningful drugs designed to help mitigate the spread of the outbreak."

The company's case for Ampligen in Ebola

The release reviews previously published Biosafety Level 4 preclinical findings. The company says those findings showed 100% protective survival with early administration of Ampligen in a lethal Ebola mouse model. It also cites a study at the US government USAMRIID facility, which showed that intraperitoneal Ampligen could have a prophylactic or early-onset impact on Ebola disease. Equels said intranasal Ampligen might more easily provide preventive protection in regions where infusion therapy is impractical.

Management describes Ampligen's mechanism as a PAMP restricted TLR3 agonist designed to activate innate immune pathways. The company says the approach may have relevance across multiple Ebola variants and other emerging viral threats. The release notes that AIM has orphan drug designation for Ebola virus disease from both the U.S. Food and Drug Administration and the European Medicines Agency.

The video also explores the potential future role of scalable antiviral and immune-modulating approaches in biodefense, preparedness and emerging infectious disease response. Those points are the company's own views, and the release does not present them as results of a new trial.

Background on the company

AIM is an immuno-pharma company based in Ocala, Florida. Its annual report describes Ampligen as a double-stranded RNA molecule being developed for globally important cancers, viral diseases and disorders of the immune system. The company has chosen to concentrate its clinical work on late-stage pancreatic cancer. The 10-K also notes that in March 2026 the company agreed with the PPD clinical research business of Thermo Fisher Scientific to design its anticipated Phase 3 trial in that disease. The 10-K also says the company has evaluated Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome and for Post-COVID fatigue, and as a vaccine adjuvant with AstraZeneca's FluMist for influenza, including avian influenza.

Financial position

The XBRL figures from the annual report show revenue of $88,000 for 2025, compared with $170,000 for 2024. Research and development expense was $3.9 million in 2025 and $6.2 million in 2024. The net loss was $14.0 million in 2025 and $17.3 million in 2024, and cash used in operations was $11.0 million in 2025 and $14.9 million in 2024. At year-end 2024, the company held cash and cash equivalents of $1.7 million and short-term investments of $2.3 million.

The risks ahead

The Ebola work rests on previously published preclinical findings, and the release does not name a new study, a regulatory step or a date. The company itself says no assurance can be given that current or planned trials will be successful, and it lists lack of adequate funding among the factors that can stop them. AIM reported a net loss of $14.0 million and cash used in operations of $11.0 million for 2025, against revenue of $88,000. The annual report says Erasmus MC expects detailed pancreatic cancer study data later this year, and a Phase 3 trial is still to be designed.

Report an error

Companies in this story

AIMAIM ImmunoTech Inc.AMEX · United StatesOpen the starter desk